Voyageur Pharmaceuticals on podcasts

About

Voyageur Pharmaceuticals Ltd. | TSXV: VM | OTC PINK:VYYRF Voyageur Pharmaceuticals (TSXV: VM) is a Canadian company focused on becoming a low-cost, vertically integrated producer of barium and iodine Active Pharmaceutical Ingredients (APIs) and finished imaging contrast agents. The Company has developed five barium contrast products that hold Health Canada licenses and are currently generating revenue in Canada. Voyageur is positioned to become North America's first vertically integrated, low-cost manufacturer of both barium and iodine contrast media, a significant competitive advantage. By owning 100% of the high-grade, metal-free Frances Creek barite project, the Company controls its own secure, domestic source of pharmaceutical-grade barium sulfate. In parallel, Voyageur's patent-pending Mueller process enables low-cost extraction of iodine from mineral brine water. Combined with its proprietary Streamline manufacturing technology, the Company plans to process that iodine directly into finished iodine contrast drugs within a single, integrated production chain. This end-to-end ownership from raw material extraction through proprietary processing to finished pharmaceutical products, is expected to deliver materially lower operating costs than competitors who purchase intermediates on the open market. At the same time, it is anticipated to create a reliable, North American-based supply chain for critical medical imaging agents, significantly reducing geopolitical, logistics, and shortage risks for hospitals and patients in the United States and Canada. This strategy embodies Voyageur's motto, "From Earth to Bottle," reflecting its commitment to responsible, traceable, and secure sourcing and manufacturing from North American resources.